Hospitals On Guard As CISA Orders Agencies To Patch VMware Software

The health care industry is on guard in the wake of a new emergency directive from the Cybersecurity and Infrastructure Security Agency that identifies vulnerabilities in specific VMware products and orders federal agencies to immediately implement mitigations. While the alert was sent to government entities, the hospital lobby warned its members Thursday (May 19) to also act quickly because VMware is also a popular cloud-based software used by private health care entities. John Riggi, American Hospital Association’s national advisor for...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Secondary Author(s): 
Topics: 

Hospitals On Guard As CISA Orders Agencies To Patch VMware Software

The health care industry is on guard in the wake of a new emergency directive from the Cybersecurity and Infrastructure Security Agency that identifies vulnerabilities in specific VMware products and orders federal agencies to immediately implement mitigations. While the alert was sent to government entities, the hospital lobby warned its members Thursday (May 19) to also act quickly because VMware is also a popular cloud-based software used by private health care entities. John Riggi, American Hospital Association’s national advisor for...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 05/27/2022
FDA Volume: 
Vol. 28, No. 21
CMS Issue: 
Inside CMS - 05/26/2022
CMS Volume: 
Vol. 25, No. 21
Author: 
Secondary Author(s): 

HHS To Spend $300 Million On Combating Antimicrobial Infections

HHS announced Thursday (May 19) that it is committing up to $300 million over 10 years for researching and developing therapeutics, preventatives and diagnostics to combat antimicrobial resistant infections. The department will spend $20 million this year on the initiative, which will be spearheaded by the Boston University-led Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which was launched by the Biomedical Advanced Research and Development Authority (BARDA) in 2016. The Biden administration has been eying ways to develop new antimicrobials. This...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 05/23/2022
IDP Volume: 
Vol. 5, No. 21
Author: 




White House Explains How DPA Invocation Will Stem Formula Shortage

The invocation of the Defense Production Act will help speed up the manufacture of baby formula amid the national shortage by empowering the government to direct resources to formula manufacturers and make they’re at the top of the list for ingredients and other materials that are needed in the production process, senior administration officials said during a press briefing Thursday (May 19). Officials said the administration is actively in conversations with companies that produce formula and wouldn’t say which specific...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 05/27/2022
FDA Volume: 
Vol. 28, No. 21
Author: 

White House Commits $1.5 Billion To OUD Treatment, Overdose Prevention

HHS will make $1.5 billion in new funding available to help states tackle substance use disorder and overdose rates, which President Joe Biden named as one of his health care agenda items for the year, HHS announced Thursday (May 19). The State Opioid Response funding will be used to help states and territories more easily access FDA-approved medications used to treat opioid use disorder. The funding will be available through the Substance Abuse and Mental Health Services Administration, HHS says,...
Article Type: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 05/26/2022
CMS Volume: 
Vol. 25, No. 21
Author: 

Burr: Accelerated Approval Reforms Left Out Because FDA Didn’t Request Them

Sen. Richard Burr (R-NC) said he didn’t include drug accelerated approval reforms in the draft FDA user fee bill he wrote with Senate health committee Chair Patty Murray (D-WA) because he likes the accelerated approval program and FDA did not ask for changes to it. However, the agency did request that Congress reform the program, both in the president’s budget request and at congressional hearings, and the House version of the user fee bill gives FDA more power over accelerated...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 05/23/2022
IDP Volume: 
Vol. 5, No. 21
Author: 




Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.